Skip to content

Study · Randomized controlled trial · n = 40 · 2016

2 results

Effect of Teriparatide on Bone Formation in the Human Femoral Neck.

Cosman F, Dempster DW, Nieves JW, Zhou H, Zion M, Roimisher C, Houle Y, Lindsay R, Bostrom M

The Journal of clinical endocrinology and metabolism22 Feb 2016Cited by 26 (Europe PMC)

PMID26900640 (opens in a new tab)PMCIDPMC4880158 (opens in a new tab)DOI10.1210/jc.2015-3698 (opens in a new tab)PepBankPUB-26900640
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients awaiting hip replacement, teriparatide increased cancellous femoral neck bone formation rate by 100% versus placebo.

    In plain wordsIn patients awaiting hip replacement, teriparatide increased cancellous bone formation compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCancellous bone formation rate
    Study

    n = 40

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · average of 40 daysAs given in this study (human).

    Measurements

    BFR/BS higher with teriparatide versus placebo
    100%
    cancellous envelope

    Source sentences

    Summary
    In cancellous and endocortical envelopes, BFR/BS was 100% higher in the TPTD vs PBO group (P < .05).
    3 context sentences
    Summary · context
    To study the effects of TPTD on the proximal femur, we performed a double-blind trial of TPTD vs placebo (PBO) in patients with osteoarthritis from whom femoral neck (FN) samples were obtained at total hip replacement (THR) surgery.
    Summary · context
    Participants were randomly assigned to receive TPTD or PBO for an average of 40 days before THR.
    Summary · context
    The primary outcome measure was bone formation rate/bone surface (BFR/BS).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients awaiting hip replacement, teriparatide increased endocortical femoral neck bone formation rate by 100% versus placebo.

    In plain wordsIn patients awaiting hip replacement, teriparatide increased endocortical bone formation compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEndocortical bone formation rate
    Study

    n = 40

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · average of 40 daysAs given in this study (human).

    Measurements

    BFR/BS higher with teriparatide versus placebo
    100%
    endocortical envelope

    Source sentences

    Summary
    In cancellous and endocortical envelopes, BFR/BS was 100% higher in the TPTD vs PBO group (P < .05).
    3 context sentences
    Summary · context
    To study the effects of TPTD on the proximal femur, we performed a double-blind trial of TPTD vs placebo (PBO) in patients with osteoarthritis from whom femoral neck (FN) samples were obtained at total hip replacement (THR) surgery.
    Summary · context
    Participants were randomly assigned to receive TPTD or PBO for an average of 40 days before THR.
    Summary · context
    The primary outcome measure was bone formation rate/bone surface (BFR/BS).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.